Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

By Yukiya Yamamoto, H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, F. Yagasaki, C. Shimazaki and 10 more. Blood, 2001

1,075 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/52a5254866b2f825bed94568e341920b9056828e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

M. Caligiuri

Citations in the corpus

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005, neutral): “Median platelet count, 1000/ L (range) 30 (1-619)”
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. (2003, background): “The catalytic D835 point mutation is also associated with leukocytosis and poor prognosis, though not as statistically significant as FLT3-ITD ((25)).”
The role of FLT3 in haematopoietic malignancies (2003, background): “TKD mutations occur in patients with AML (5–10%), MDS (2–5%) and ALL (1–3%”
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, neutral): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “9 del(9), +11 80 BMR 90%→45% BM blasts (60mg) 27 WT 70 / F M4 10.”
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (2002, neutral): “CD34 cells (%) 30 (0-98) 20‡ (0-96) 22 (0-91) 10 (3-73)”
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. (2001, background): “03 Percentage of DFS at 12 months (95% confidence interval) 71 (62, 80) 39 (29, 48)”